SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
A group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin.
This code should rarely be used for cutaneous T-cell lymphoma, NOS. Diagnosis of a more specific T-cell neoplasm should be possible. Use this NOS term only for HISTORIC CASES, DCO cases, or path-only cases when additional information is not available.
There are two variants for this code: 1. Primary or cutaneous CD8-positive aggressive epidermotropic cytotoxicT-cell lymphoma. Characterized by localized or disseminated eruptive papules, nodules with tumors showing central ulceration and necrosis or by superficial hyperkeratotic patches and plaques. Dissemination to other visceral sites (lung, testis, CNS, and oral mucosa) possible. Lymph nodes seldom affected. Aggressive clinical course with median survival of 32 months.
2. Primary cutaneous CD4-positive small/medium T-cell lymphoma. Clinical presentation is usually a solitary plaque or nodule, commonly on the face, neck, or upper trunk. Involvement of lower extremities is rare. There should be an absence of patches (if patches are seen, see Mycosis Fungoides, 9700/3).
Note: When there is a pre-2010 tumor coded to 9709/3 there should be careful follow-back to determine whether this new diagnosis is a new primary or a more specific diagnosis of T-cell cutaneous lymphoma.
Patients with a single lesion have an excellent prognosis and are treated with surgical excision or radiotherapy.
Definitive Diagnostic Methods
T-cell receptor (TCR) genes are clonally rearranged